chevron_leftBack
As of 24 April 2025, Defence Therapeutics Inc. has a market cap of $35.17M USD, ranking #26706 globally and #836 in Canada. It ranks #2696 in the Healthcare sector, and #876 in the Biotechnology industry.
Key Stats
Market Cap
$35.17MUSD
48.71M CAD
Enterprise Value
$35.93MUSD
49.86M CAD
EBITDA (TTM)
-$2.41MUSD
-3.34M CAD
Net Income (TTM)
-$2.95MUSD
-4.09M CAD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Sebastien Plouffe
open_in_new
Founded
2017
Website
defencetherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.1% | -5.3% | -24% | 13% | 48% | -38% |
Upcoming Earnings
Earnings Date
Tue, May 27
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
DTC
Defence Therapeutics Inc
ISIN: CA24463V1013
Shares Out.:
Shares Outstanding:
54.725M1
Shares Float:
51.988M2
|
0.8900 CAD | |
|
DTC
Defence Therapeutics Inc
ISIN: CA24463V1013
|
0.9300 CAD | |
|
DTCFF
Defence Therapeutics Inc
ISIN: CA24463V1013
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.6447 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. It also offers Accuvac for dendritic cell cancer vaccines; a protein‐based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
